Star Equity (NASDAQ:STRR – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Profitability
This table compares Star Equity and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Star Equity | -14.65% | -5.74% | -3.34% |
| Aclaris Therapeutics | -183.28% | -53.18% | -41.74% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Star Equity and Aclaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Star Equity | 0 | 0 | 0 | 0 | N/A |
| Aclaris Therapeutics | 0 | 6 | 0 | 0 | 2.00 |
Insider & Institutional Ownership
3.8% of Star Equity shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 28.8% of Star Equity shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Star Equity has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.
Valuation & Earnings
This table compares Star Equity and Aclaris Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Star Equity | $47.15 million | 0.27 | $25.13 million | $6.50 | 0.61 |
| Aclaris Therapeutics | $32.02 million | 2.58 | -$88.48 million | ($1.09) | -1.06 |
Star Equity has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Star Equity, indicating that it is currently the more affordable of the two stocks.
Summary
Star Equity beats Aclaris Therapeutics on 8 of the 12 factors compared between the two stocks.
About Star Equity
Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Star Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Star Equity and related companies with MarketBeat.com's FREE daily email newsletter.
